Invesco Biotechnology & Genome ETF
PBE
73 hedge funds and large institutions have $52.8M invested in Invesco Biotechnology & Genome ETF in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 10 closing their positions.
2.11% more ownership
Funds ownership: 22.03% → 24.14% (+2.1%)
1% less capital invested
Capital invested by funds: $53.4M → $52.8M (-$612K)
5% less funds holding
Funds holding: 77 → 73 (-4)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$2.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.85M |
| 3 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$819K |
| 4 |
LPL Financial
San Diego,
California
|
+$567K |
| 5 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.98M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.16M |
| 3 |
ACM
Anfield Capital Management
Irvine,
California
|
-$427K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
-$323K |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$260K |
PBE Hedge Fund Activity: Q3 2020 in Review
73 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2020, worth a combined $52.8M — down 1.1% from $53.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PBE and 6 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 16 added.
The largest buyer was Wells Fargo, adding an estimated $2.31M. The largest seller was UBS Group, cutting an estimated $1.98M.
- 73 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2020, down from 77 in Q2 2020.
- Funds reported $52.8M of Invesco Biotechnology & Genome ETF stock for Q3 2020, down 1.1% quarter-over-quarter.
- 6 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2020 and 10 closed out, a net change of -4 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q3 2020 was Wells Fargo, an estimated $2.31M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q3 2020 was UBS Group, an estimated $1.98M sold.
Based on aggregated 13F filings for Q3 2020.